CNBX Pharmaceuticals Inc.

What they do

CNBX Pharmaceuticals is a clinical-stage company focused on the discovery and development of cannabinoid-based products for cancer treatment. Its lead product candidate is Cannabics SR, an oral capsule for advanced cancer and cancer anorexia cachexia syndrome, and it is also developing RCC-33 for colorectal cancer. The company's R&D is conducted in a government-licensed lab in Israel.

Revenue drivers

• Cannabics SR — The only commercialized product, but reported revenue was zero in fiscal 2025 and in the most recent quarters, indicating no meaningful sales.
• RCC-33 — An anti-neoplastic drug candidate for colorectal cancer in development; no revenue generated from this product.
• No recurring revenue sources — The company has no significant revenue; historical revenue was sporadic and immaterial, e.g., $410k in 2023 and $130k in 2024, with none in 2025.

Recent performance

For fiscal year 2025, CNBX reported zero revenue, a net loss of $313,976, and negative operating cash flow of $171,305. Quarterly revenue has been $0 for all quarters reported in 2025 and 2026. At May 31, 2026, cash was only $9,487, total assets were $12,795, and stockholders' equity was negative $2.7 million. The company's auditor has expressed substantial doubt about its ability to continue as a going concern.

Strategy

Management states the company is dedicated to developing and commercializing novel cannabinoid-based products for cancer. They are continuing R&D on Cannabics SR and RCC-33. To fund operations, they have relied on private placements of common stock, warrants, and equity investments. The company has entered material agreements in 2025 and 2026, but details are not in the provided excerpts.

Risks

• Going concern risk — The independent auditors have expressed substantial doubt about the company's ability to continue as a going concern, which could impair its ability to raise needed capital.
• No significant revenue — The company has not generated significant revenue since inception and may never achieve profitability, as losses are expected to continue with R&D spending.
• Cash and liquidity constraints — Cash and equivalents were only $9,487 as of May 31, 2026, with current liabilities of $2.67 million, indicating a severe liquidity shortfall.
• Dependence on financing — The company has financed operations primarily through private placements and direct equity investments, and if it fails to raise additional funds, it may have to liquidate.

Outlook

Management expects expenses to increase as R&D continues, requiring significant capital. The company has not provided specific forward guidance in the excerpts. The forward-looking statements highlight the need for additional financing and the uncertainty of market acceptance for any products.